<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Oncol</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1878-0261</journal-id>
<journal-id journal-id-type="publisher-id">MOL2</journal-id>
<journal-title-group>
<journal-title>Molecular Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1574-7891</issn>
<issn pub-type="epub">1878-0261</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30051603</article-id>
<article-id pub-id-type="pmc">6120252</article-id>
<article-id pub-id-type="doi">10.1002/1878-0261.12363</article-id>
<article-id pub-id-type="publisher-id">MOL212363</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<styled-content style="fixed-case">PGC</styled-content>1β regulates multiple myeloma tumor growth through <styled-content style="fixed-case">LDHA</styled-content>‐mediated glycolytic metabolism</article-title>
<alt-title alt-title-type="left-running-head">H. Zhang <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="mol212363-cr-0001">
<name>
<surname>Zhang</surname>
<given-names>Hongyu</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0002">
<name>
<surname>Li</surname>
<given-names>Ling</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0003">
<name>
<surname>Chen</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0004">
<name>
<surname>Li</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0005">
<name>
<surname>Feng</surname>
<given-names>Jia</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0006">
<name>
<surname>Sun</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0007">
<name>
<surname>Zhao</surname>
<given-names>Rong</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0008">
<name>
<surname>Zhu</surname>
<given-names>Yin</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0009">
<name>
<surname>Lv</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0010">
<name>
<surname>Zhu</surname>
<given-names>Zhigang</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mol212363-cr-0011">
<name>
<surname>Huang</surname>
<given-names>Xiaodong</given-names>
</name>
<xref ref-type="aff" rid="mol212363-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="mol212363-cr-0012">
<name>
<surname>Xie</surname>
<given-names>Weiguo</given-names>
</name>
<address>
<email>wgxie@hotmail.com</email>
</address>
<xref ref-type="aff" rid="mol212363-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="mol212363-cr-0013">
<name>
<surname>Xiang</surname>
<given-names>Wei</given-names>
</name>
<address>
<email>xiangwei8@163.com</email>
</address>
<xref ref-type="aff" rid="mol212363-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="mol212363-cr-0014">
<name>
<surname>Yao</surname>
<given-names>Paul</given-names>
</name>
<address>
<email>vasilis112@yahoo.com</email>
</address>
<xref ref-type="aff" rid="mol212363-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="mol212363-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="mol212363-aff-0003">
<sup>3</sup>
</xref>
</contrib>
</contrib-group>
<aff id="mol212363-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Hematology</named-content>
<institution>Peking University Shenzhen Hospital</institution>
<country country="CN">China</country>
</aff>
<aff id="mol212363-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>Hainan Maternal and Child Health Hospital</institution>
<named-content content-type="city">Haikou</named-content>
<country country="CN">China</country>
</aff>
<aff id="mol212363-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Institute of Rehabilitation Center</named-content>
<institution>Tongren Hospital of Wuhan University</institution>
<country country="CN">China</country>
</aff>
<aff id="mol212363-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Geriatrics</named-content>
<named-content content-type="organisation-division">National Key Clinical Specialty</named-content>
<named-content content-type="organisation-division">Guangzhou First People's Hospital</named-content>
<institution>Guangzhou Medical University</institution>
<country country="CN">China</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
P. Yao, Department of Hematology, Peking University Shenzhen Hospital, Shenzhen 518036, China<break></break>
Fax: +86 27 88842061<break></break>
Tel: +86 13049687987<break></break>
E‐mail: <email>vasilis112@yahoo.com</email><break></break>
W. Xiang, Department of Pediatrics, Hainan Maternal and Child Health Hospital, Haikou 570206, China<break></break>
Fax: +86 898 36689190<break></break>
Tel: +86 18608981299<break></break>
E‐mail: <email>xiangwei8@163.com</email><break></break>
and<break></break>
W. Xie, Institute of Rehabilitation Center, Tongren Hospital of Wuhan University, Wuhan 430060, China<break></break>
Fax: +86 27 88842061<break></break>
Tel: +86 18071085225<break></break>
E‐mail: <email>wgxie@hotmail.com</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2018</year>
</pub-date>
<volume>12</volume>
<issue>9</issue>
<issue-id pub-id-type="doi">10.1002/mol2.2018.12.issue-9</issue-id>
<fpage>1579</fpage>
<lpage>1595</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>4</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>7</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 Federation of European Biochemical Societies <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. Published by FEBS Press and John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:MOL2-12-1579.pdf" xlink:type="simple"></self-uri>
<abstract id="mol212363-abs-0001">
<p>Multiple myeloma (<styled-content style="fixed-case">MM</styled-content>) is an incurable hematologic malignancy due to inevitable relapse and chemoresistance development. Our preliminary data show that <styled-content style="fixed-case">MM</styled-content> cells express high levels of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content>. In this study, we investigated the mechanism behind <styled-content style="fixed-case">PGC</styled-content>1β‐mediated <styled-content style="fixed-case">LDHA</styled-content> expression and its contribution to tumorigenesis, to aid in the development of novel therapeutic approaches for <styled-content style="fixed-case">MM</styled-content>. Real‐time <styled-content style="fixed-case">PCR</styled-content> and western blotting were first used to evaluate gene expression of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> in different <styled-content style="fixed-case">MM</styled-content> cells, and then, luciferase reporter assay, chromatin immunoprecipitation, <styled-content style="fixed-case">LDHA</styled-content> deletion report vectors, and si<styled-content style="fixed-case">RNA</styled-content> techniques were used to investigate the mechanism underlying <styled-content style="fixed-case">PGC</styled-content>1β‐induced <styled-content style="fixed-case">LDHA</styled-content> expression. Furthermore, knockdown cell lines and lines stably overexpressing <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> lentivirus were established to evaluate <italic>in vitro</italic> glycolysis metabolism, mitochondrial function, reactive oxygen species (<styled-content style="fixed-case">ROS</styled-content>) formation, and cell proliferation. In addition<italic>, in vivo</italic> xenograft tumor development studies were performed to investigate the effect of <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> expression on tumor growth and mouse survival. We found that <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> are highly expressed in different <styled-content style="fixed-case">MM</styled-content> cells and <styled-content style="fixed-case">LDHA</styled-content> is upregulated by <styled-content style="fixed-case">PGC</styled-content>1β through the <styled-content style="fixed-case">PGC</styled-content>1β/<styled-content style="fixed-case">RXR</styled-content>β axis acting on the <styled-content style="fixed-case">LDHA</styled-content> promoter. Overexpression of <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> significantly potentiated glycolysis metabolism with increased cell proliferation and tumor growth. On the other hand, knockdown of <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> largely suppressed glycolysis metabolism with increased <styled-content style="fixed-case">ROS</styled-content> formation and apoptosis rate, in addition to suppressing tumor growth and enhancing mouse survival. This is the first time the mechanism underlying <styled-content style="fixed-case">PGC</styled-content>1β‐mediated <styled-content style="fixed-case">LDHA</styled-content> expression in multiple myeloma has been identified. We conclude that <styled-content style="fixed-case">PGC</styled-content>1β regulates multiple myeloma tumor growth through <styled-content style="fixed-case">LDHA</styled-content>‐mediated glycolytic metabolism. Targeting the <styled-content style="fixed-case">PGC</styled-content>1β/<styled-content style="fixed-case">LDHA</styled-content> pathway may be a novel therapeutic strategy for multiple myeloma treatment.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="mol212363-kwd-0001">glycolysis</kwd>
<kwd id="mol212363-kwd-0002">lactate dehydrogenase</kwd>
<kwd id="mol212363-kwd-0003">
<styled-content style="fixed-case">LDHA</styled-content>
</kwd>
<kwd id="mol212363-kwd-0004">mitochondria</kwd>
<kwd id="mol212363-kwd-0005">multiple myeloma</kwd>
<kwd id="mol212363-kwd-0006"><styled-content style="fixed-case">PGC</styled-content>1β</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>The National Natural Science Foundation of China</funding-source>
<award-id>81772097</award-id>
</award-group>
<award-group>
<funding-source>Natural Science Foundation of Hubei Province of China</funding-source>
<award-id>2016CFB473</award-id>
</award-group>
<award-group>
<funding-source>Bureau of Public Health of Hainan Province</funding-source>
<award-id>14A110065</award-id>
</award-group>
<award-group>
<funding-source>Shenzhen Scientific and Technical Innovation Committee</funding-source>
<award-id>JCYJ20150403091443305</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="7"></fig-count>
<table-count count="0"></table-count>
<page-count count="17"></page-count>
<word-count count="9915"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>mol212363</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.7.1 mode:remove_FC converted:03.09.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group id="mol212363-ntgp-0001">
<fn fn-type="equal" id="mol212363-note-1001">
<p>Hongyu Zhang, Ling Li and Qi Chen contributed to this manuscript equally</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<def-list id="mol212363-dl-0001" list-content="abbreviations">
<title>Abbreviations</title>
<def-item>
<term>ChIP</term>
<def>
<p>chromatin immunoprecipitation</p>
</def>
</def-item>
<def-item>
<term>ECAR</term>
<def>
<p>extracellular acidification</p>
</def>
</def-item>
<def-item>
<term>ERRα</term>
<def>
<p>estrogen‐related receptor α</p>
</def>
</def-item>
<def-item>
<term>LDH</term>
<def>
<p>lactate dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>MM</term>
<def>
<p>multiple myeloma</p>
</def>
</def-item>
<def-item>
<term>MNCs</term>
<def>
<p>mononuclear cells</p>
</def>
</def-item>
<def-item>
<term>mtTFA</term>
<def>
<p>mitochondrial transcription factor A</p>
</def>
</def-item>
<def-item>
<term>NBL</term>
<def>
<p>normal B lymphocytes</p>
</def>
</def-item>
<def-item>
<term>OCR</term>
<def>
<p>oxygen consumption rate</p>
</def>
</def-item>
<def-item>
<term>OXPHOS</term>
<def>
<p>oxidative phosphorylation</p>
</def>
</def-item>
<def-item>
<term>PGC1β</term>
<def>
<p>peroxisome proliferator‐activated receptor‐γ (PPARγ) coactivator‐1β</p>
</def>
</def-item>
<def-item>
<term>PPRC1</term>
<def>
<p>Homo sapiens peroxisome proliferator‐activated receptor‐gamma, coactivator‐related 1</p>
</def>
</def-item>
<def-item>
<term>ROS</term>
<def>
<p>reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term>RXRβ</term>
<def>
<p>retinoic X receptor β</p>
</def>
</def-item>
</def-list>
<sec id="mol212363-sec-0001">
<title>Introduction</title>
<p>Multiple myeloma (MM) is a hematologic malignancy characterized by antibody‐secreting plasma cells with proliferation in abnormal bone marrow (Gong <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0015">2016</xref>; Landgren and Morgan, <xref ref-type="ref" rid="mol212363-bib-0020">2014</xref>). The median overall survival rate has been significantly improved during the last decades due to advanced understanding of its molecular basis as well as development of novel therapies, including immune modulator agents, proteasome inhibitor drugs, and allogeneic stem cell transplantation (Sherbenou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0030">2016</xref>). However, MM remains largely incurable due to inevitable relapse and development of chemoresistance (Teoh <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0033">2014</xref>). Development of novel therapeutic approaches and targeting of abnormal cancer metabolism in molecular and cellular heterogeneity of MM may provide us with new strategies for overcoming this disease (Dalva‐Aydemir <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0006">2015</xref>; Dimopoulos <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0009">2018</xref>; Naymagon and Abdul‐Hay, <xref ref-type="ref" rid="mol212363-bib-0028">2016</xref>).</p>
<p>Lactate dehydrogenase (LDH) is a key enzyme that regulates the glycolysis and conversion of pyruvate and NADH to lactate and NAD<sup>+</sup>. LDH isoform A (LDHA) has been reported to be upregulated in many cancer cells (Bui and Thompson, <xref ref-type="ref" rid="mol212363-bib-0003">2006</xref>) and favors tumor invasion and metastasis by promoting the metabolic switch to glycolysis (Jin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0017">2017</xref>). LDHA is highly expressed in MM cell lines, and targeting LDHA is considered a novel therapeutic approach, while the potential mechanism for LDHA upregulation remains unclear (Fujiwara <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0012">2013</xref>; Maiso <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0027">2015</xref>).</p>
<p>The peroxisome proliferator‐activated receptor‐γ (PPARγ) coactivator‐1β (PGC1β) (Lin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0024">2002</xref>), together with PGC1α, regulates many downstream target genes and plays a critical role as a transcriptional coactivator in the maintenance of glucose, lipid, and energy metabolism (Lin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0023">2005a</xref>). Recent studies have shown that PGC1β is upregulated in cancer cells and promotes tumorigenesis by regulation of mitochondrial biogenesis and glycolysis metabolism (Bellafante <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0001">2014</xref>; Chang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0004">2011</xref>; Deblois <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0007">2010</xref>; Deblois <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0008">2013</xref>), while the detailed mechanism still needs to be fully understood.</p>
<p>In an effort to develop a novel targeting or therapeutic strategy for multiple myeloma (MM), we measured the related gene expression in different MM cell lines. Our preliminary data showed that MM cells have upregulated expression of PGC1β and LDHA. Further investigation showed that LDHA expression was coactivated by PGC1β through increased binding ability of transcription factor RXRβ (retinoic X receptor β) (Joseph <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0018">1998</xref>; Usmani <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0034">2012</xref>) on the LDHA promoter. <italic>In vitro</italic> cell culture studies showed that expression of PGC1β or LDHA modulates glycolysis metabolism, mitochondrial function, and <italic>in vitro</italic> tumor growth. Furthermore, <italic>in vivo</italic> tumor xenograft studies showed that overexpression of PGC1β or LDHA potentiated tumor colony formation with decreased mouse survival, while knockdown of these genes reversed this effect. To our knowledge, this is the first time the detailed mechanism for PGC1β‐regulated LDHA expression and its potential role in MM development has been identified. We conclude that PGC1β regulates multiple myeloma tumor growth through LDHA‐mediated glycolytic metabolism.</p>
</sec>
<sec id="mol212363-sec-0002">
<title>Materials and methods</title>
<sec id="mol212363-sec-0003">
<title>Reagents and materials</title>
<p>Multiple myeloma cell lines, including MM.1R (lightly attached cell lines), U266B1, and RPMI8226, were purchased from ATCC and cultured in RPMI‐1640 medium supplemented with 100 U·mL<sup>−1</sup> penicillin, 100 μg·mL<sup>−1</sup> streptomycin, and 10% FBS (fetal bovine serum). All cells were maintained in a humidified incubator with 5% CO<sub>2</sub> at 37 °C. Hypoxic conditions were induced by incubating in 94% N<sub>2</sub>, 5% CO<sub>2</sub>, and 1% O<sub>2</sub> for 24 h. The antibodies for PGC1β (ab176328) were obtained from Abcam (Shanghai, China), and β‐actin (sc‐47778), Ki‐67 (sc‐101861), LDHA (sc‐137243), RXRα (sc‐515928), and RXRβ (sc‐742) were obtained from Santa Cruz Biotechnology (Shanghai, China). siRNA against PGC1β, RXRα, and RXRβ or nonspecific siRNA (from Ambion, Beijing, China) was transfected using Oligofectamine reagent (Invitrogen, Beijing, China) according to the manufacturers’ instructions. Protein concentration was measured by the Coomassie Protein Assay kit (Pierce, Holmdel, NJ, USA) using bovine serum albumin as a standard. The vitamin E derivative Trolox (#238813) was obtained from Sigma (Shanghai, China).</p>
</sec>
<sec id="mol212363-sec-0004">
<title>Human cell isolation</title>
<p>Cell isolation protocol was approved by the Ethics Committee of Peking University Shenzhen Hospital. All patients (from Peking University Shenzhen Hospital) provided written informed consent in accordance with the Declaration of Helsinki. For isolation of primary multiple myeloma cells (CD138+), the bone marrow aspirates (collected from proven multiple myeloma patients) were used to purify CD138+ cells using an EasySep™ Human CD138 Positive Selection Kit (#18357). For isolation of B cells, the normal B lymphocytes (NBL) were purified from peripheral blood mononuclear cells using the EasySep™ Human B Cell Enrichment Kit (#19054). The mononuclear cells (MNCs) were isolated from fresh blood using Lymphoprep™ reagents (#07861). All the reagents were obtained from STEMCELL Technologies, and the related procedures were conducted as per the manufacturer's instructions.</p>
</sec>
<sec id="mol212363-sec-0005">
<title>Construction of LDHA reporter plasmids</title>
<p>The human genomic DNA was prepared from human primary mononuclear cells (MNCs). The LDHA promoter (2000 bp upstream of TSS + first exon) from the Ensembl Transcription ID ENST00000280704 was amplified by PCR through the following primers with the introduction of <italic>Kpn</italic>I/<italic>Hind</italic>III restriction sites as indicated by underline: LDHA Forward: 5′‐ gcgc‐ <underline underline-style="single">GGTACC</underline> ‐ gtg gtc aca ttt ggt agg cag ‐3′ (<italic>Kpn</italic>I) and LDHA Reverse: 5′‐ gcgc‐ <underline underline-style="single">AAGCTT</underline>‐ cgg gaa tgc acg tcg ggc ggt‐3′(<italic>Hind</italic>III); and the purified fragment was subcloned into the pGL3‐basic vector (Promega, Shanghai, China). LDHA deletion reporter constructs were generated by three‐round PCR methods. Detailed information about these clones is available upon request.</p>
</sec>
<sec id="mol212363-sec-0006">
<title>Human PGC1β/LDHA expression lentivirus</title>
<p>The human cDNA for PGC1β and LDHA was obtained from Open Biosystems (Shanghai, China) and was subcloned into the pLVX‐Puro vector (from Clontech, Shanghai, China). PGC1β was amplified using the below primers with the introduction of XhoI and XbaI restriction sites as indicated by underline: PGC1β forward primer: 5′‐ ATCG‐ <underline underline-style="single">CTCGAG</underline>‐ atg gcg ggg aac gac tgc ggc ‐3′ (XhoI) and PGC1β reverse primer: 5′‐ ATCG‐ <underline underline-style="single">TCTAGA</underline>‐ tca atg cag gct ctg ctg ggc ‐3′ (XbaI). LDHA was amplified using the below primers with the introduction of XhoI and XbaI restriction sites as indicated by underline: LDHA forward primer: 5′‐ ATCG‐ <underline underline-style="single">CTCGAG</underline>‐ atg gca act cta aag gat cag ‐3′ (XhoI) and LDHA reverse primer: 5′‐ ATCG‐ <underline underline-style="single">TCTAGA</underline> ‐ tta aaa ttg cag ctc ctt ttg ‐3′ (XbaI). The PGC1β, LDHA, or empty control (CTL) was expressed through Lenti‐X™ Lentiviral Expression Systems (from Clontech) as per the manufacturer's instructions.</p>
</sec>
<sec id="mol212363-sec-0007">
<title>Establishment of stable PGC1β or LDHA knockout cell line</title>
<p>The stable knockout cells for PGC1β, LDHA, or related nontarget control (CTL) were prepared through infection of MM cell lines by shRNA lentivirus particles from Sigma for either human PGC1β (SHCLNV‐NM_133263), LDHA (SHCLNV‐NM_005566), or nontarget control (SHC216V). The positive knockout cells were selected by 10 μg·mL<sup>−1</sup> of puromycin, and the stable PGC1β or LDHA knockout cell line was confirmed by more than 65% mRNA reduction compared to the control group using real‐time PCR (see primers in Table <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S1</xref>).</p>
</sec>
<sec id="mol212363-sec-0008">
<title>RT reaction and real‐time quantitative PCR</title>
<p>Total RNA from treated cells was extracted using the RNeasy Micro Kit (Qiagen, Shanghai, China), and the RNA was reverse‐transcribed using an Omniscript RT kit (Qiagen). All the primers were designed using <sc>primer3plus</sc> software with the Tm at 60 °C, primer size of 21 bp, and the product length in the range of 140–160 bp (see Table <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S1</xref>). The primers were validated with the amplification efficiency in the range of 1.9–2.1, and the amplified products were confirmed with agarose gel. The real‐time quantitative PCR was run on iCycler iQ (Bio‐Rad, Shanghai, China) with the QuantiTect SYBR Green PCR kit (Qiagen). The PCR was performed by denaturing at 95 °C for 8 min, followed by 45 cycles of denaturation at 95 °C, annealing at 60 °C, and extension at 72 °C for 10 s, respectively. 1 μL of each cDNA was used to measure target genes. The β‐actin was used as the housekeeping gene for transcript normalization, and the mean values were used to calculate relative transcript levels with the <sup>ΔΔ</sup>CT method as per the instructions from Qiagen. In brief, the amplified transcripts were quantified by the comparative threshold cycle method using β‐actin as a normalizer. Fold changes in gene mRNA expression were calculated as 2<sup>−ΔΔCT</sup> with CT = threshold cycle, ΔCT = CT (target gene)‐CT (β‐actin), and the ΔΔCT = ΔCT (experimental)−ΔCT (reference) (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>; Zou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0041">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0009">
<title>Western blotting</title>
<p>Cells were lysed in an ice‐cold lysis buffer (0.137 <sc>m</sc> NaCl, 2 m<sc>m</sc> EDTA, 10% glycerol, 1% NP‐40, 20 m<sc>m</sc> Tris base, pH 8.0) with protease inhibitor cocktail (Sigma). The proteins were separated in 10% SDS/PAGE and further transferred to the PVDF membrane. The membrane was incubated with appropriate antibodies, washed, and incubated with HRP‐labeled secondary antibodies, and then, the blots were visualized using the ECL Plus Western Blotting Detection System (Amersham). The blots were quantitated by IMAGEQUANT, and the final results were normalized by β‐actin (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>; Zou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0041">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0010">
<title>Luciferase reporter assay</title>
<p>MM.1R were infected by either lentivirus PGC1β (↑PGC1β) or empty control (CTL) for 2 days, and then, 1.0 × 10<sup>5</sup> of infected MM.1R cells were seeded in a 6‐well plate with complete medium to grow until they reached 80% confluence. The related LDHA luciferase reporter plasmids (3 μg) and 0.2 μg pRL‐CMV‐Luc <italic>Renilla</italic> plasmid (from Promega) were transiently cotransfected. After treatment, the cells were harvested and the luciferase activity assays were carried out using the Dual‐Luciferase™ Assay System (Promega), and the transfection efficiencies were normalized using a cotransfected <italic>Renilla</italic> plasmid according to the manufacturer's instructions. The PGC1β‐induced LDHA reporter activity from PGC1β lentivirus (↑PGC1β)‐infected group was calculated as the relative percentage (% control) by comparing to the lentivirus empty control (CTL)‐infected group (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0011">
<title>Chromatin Immunoprecipitation</title>
<p>Cells were washed and crosslinked using 1% formaldehyde for 20 min and terminated by 0.1 <sc>m</sc> glycine. Cell lysates were sonicated and centrifuged. Five hundred microgram of protein was precleared by BSA/salmon sperm DNA with preimmune IgG and a slurry of Protein A Agarose beads. Immunoprecipitations were performed with the indicated antibodies, BSA/salmon sperm DNA, and a 50% slurry of Protein A Agarose beads. Input and immunoprecipitates were washed and eluted, and then incubated with 0.2 mg·mL<sup>−1</sup> Proteinase K for 2 h at 42 °C, followed by 6 h at 65 °C to reverse the formaldehyde crosslinking. DNA fragments were recovered by phenol/chloroform extraction and ethanol precipitation. A ~150‐bp fragment in the range of ‐200~0 from the transcription start site on the LDHA promoter was amplified by real‐time PCR (qPCR) using the primers provided in Table <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S1</xref> (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>; Zou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0041">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0012">
<title>Immunostaining</title>
<p>The treated MM.1R cells were transferred to coverslips coated with 0.1% gelatin, fixed by 3.7% formaldehyde at 37 °C for 15 min, permeabilized by 1% BSA + 0.2% Triton X‐100 in PBS for 1 h, and then blotted with 40 μg·mL<sup>−1</sup> (dilute 1 : 50) of Ki‐67 (MIB‐1) mouse monoclonal antibody for 2 h. The cells were then washed three times, and the FITC‐labeled anti‐mouse secondary antibody (1 : 100) was added for blotting for another 1 h. After thorough washing, the slides were visualized and photographed, and the nuclei of cells were stained with 4′,6‐diamidino‐2‐phenylindole dihydrochloride (DAPI, #D9542, from Sigma).</p>
</sec>
<sec id="mol212363-sec-0013">
<title>Seahorse analysis</title>
<p>The treated MM tumor cells were used to evaluate glycolysis metabolism by measuring the extracellular acidification (ECAR) and oxygen consumption rate (OCR) using the Seahorse‐XF96 Analyzer (Seahorse Bioscience Inc., Shanghai, China) as per the manufacturer's instructions. In brief, 2.0 × 10<sup>5</sup> cells per well were seeded in XF96 cell culture microplates and incubated at 37 °C for 24 h. The plates were placed in a carrier tray and centrifuged at 300xg for 1 min with no brake. The culture medium was changed to XF Assay Medium (supplemented with 5 m<sc>m</sc> glucose) with care taken to not disturb the cells on the bottom, and the cells were equilibrated for 30 min at 37 °C under normoxic conditions. The plates were loaded into the XF96 analyzer, and the OCR and ECAR were evaluated and recorded (Zubair <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0042">2016</xref>).</p>
</sec>
<sec id="mol212363-sec-0014">
<title>Lactate production assay</title>
<p>The treated MM cell lines were seeded at 5 × 10<sup>5</sup> cells·mL<sup>−1</sup> in 12‐well plates. Lactate production in the culture medium was assessed using the Lactate Colorimetric/Fluorometric Assay Kit (#K607; BioVision, Shanghai, China) according to the manufacturer's instructions. Lactate production from each well was measured after 1 h of medium refreshment at excitation/emission wavelengths of 535/587 nm using a FLx800 microplate fluorescence reader (BioTek, Shanghai, China). Cell number was counted, and the results were expressed as nmol/10<sup>6</sup> cells·min<sup>−1</sup> (Christofk <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0005">2008</xref>).</p>
</sec>
<sec id="mol212363-sec-0015">
<title>LDH activity assay</title>
<p>Intracellular LDH activity was assessed using the Lactate Dehydrogenase Activity Colorimetric Assay Kit (#K726; BioVision) according to the manufacturer's instructions. In brief, treated MM cell lines were cultured at 2 × 10<sup>5</sup> cells·mL<sup>−1</sup>, and then, 1 × 10<sup>6</sup> cells were harvested for cell lysate preparation. In this colorimetric assay, LDH reduces NAD to NADH and then interacts with a probe to produce a color at a wavelength of 450 nm (λ<sub>max</sub> = 450 nm), which was measured using a spectrophotometer. The data were calculated as the LDH activity per cell lysate protein amount and expressed as unit·mg<sup>−1</sup> (Fujiwara <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0012">2013</xref>; Jin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0017">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0016">
<title>Measurement of ROS generation</title>
<p>Treated cells were seeded in a 24‐well plate and incubated with 10 μ<sc>m</sc> CM‐H2DCFDA (Invitrogen) for 45 min at 37 °C, and then, the intracellular formation of reactive oxygen species (ROS) was measured at excitation/emission wavelengths of 485/530 nm using a FLx800 microplate fluorescence reader (BioTek). The data were normalized as arbitrary units (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>; Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0017">
<title>Measurement of mitochondrial function</title>
<sec id="mol212363-sec-0018">
<title>Mitochondrial DNA copies</title>
<p>The genomic DNA was extracted from treated MM.1R cells using a QIAamp DNA Mini Kit (Qiagen), and the mitochondrial DNA was extracted using the REPLI‐g Mitochondrial DNA Kit (Qiagen). The purified DNA was used for the analysis of genomic β‐actin (marker of the nuclear gene) and ATP6 (ATP synthase F0 subunit 6, marker of the mitochondrial gene), respectively, using the qPCR method as mentioned above. The primers for genomic β‐actin were as follows: forward 5′‐ ctg gac ttc gag caa gag atg ‐3′ and reverse: 5′‐ agg aag gaa ggc tgg aag agt ‐3′. The primers for ATP6 were as follows: forward 5′‐ cat tta cac caa cca ccc aac ‐3′ and reverse 5′‐ tat ggg gat aag ggg tgt agg ‐3′. The mitochondrial DNA copies were obtained from relative ATP6 copies that were normalized by β‐actin copies using the <sup>ΔΔ</sup>CT method (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>; Zou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0041">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0019">
<title>Intracellular ATP level</title>
<p>The intracellular ATP level was determined using the luciferin/luciferase‐induced bioluminescence system. An ATP standard curve was generated at concentrations of 10<sup>−12</sup>–10<sup>−3 </sup>
<sc>m</sc>. Intracellular ATP levels were calculated and expressed as nmol·mg<sup>−1</sup> protein (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>; Zou <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0041">2017</xref>).</p>
</sec>
</sec>
<sec id="mol212363-sec-0020">
<title>Measurement of apoptosis</title>
<p>Apoptosis was evaluated by TUNEL assay using the In Situ Cell Death Detection Kit™ (Roche, Shanghai, China). Cells were fixed in 4% paraformaldehyde and labeled by TUNEL reagents. Stained cells were photographed by a fluorescence microscope and further quantified by FACS analysis. Caspase‐3 activity was determined by the ApoAlert caspase assay kit (Clontech). Treated cells were harvested, and 50<sup> </sup>μg of proteins was incubated with the fluorogenic peptide substrate Ac‐DEVD‐7‐amino‐4‐trifluoromethyl coumarin (AFC). The initial rate of free AFC release was measured using a FLx800 microplate reader (BioTek) at excitation/emission wavelengths of 380/505 nm, and enzyme activity was calculated as pmol·min<sup>−1</sup>·mg<sup>−1</sup> (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>).</p>
</sec>
<sec id="mol212363-sec-0021">
<title>Cell viability and MTT assay</title>
<p>Cells were pooled in 12‐well plates following exposure to different treatments as indicated at 80% confluence. Cell viability was analyzed by the MTT (3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide) reduction assay (Liu <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0026">1997</xref>). In brief, cells in each well were aspirated and washed with PBS, and then, 0.2 mL of 0.3 mg·mL<sup>−1</sup> MTT solution was added at 25 °C for 3 h. Thereafter, the precipitated blue formazan product was extracted by incubating samples with 0.1 mL 10% SDS (dissolved by 0.01 <sc>m</sc> HCl) overnight at 37 °C. The optical density (OD) of formazan concentrations was determined at 560 nm, and the background was subtracted at 670 nm, then normalized by cell numbers, and expressed as OD/10<sup>6</sup> cells (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>; Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0022">
<title>DNA synthesis by [<sup>3</sup>H]‐thymidine incorporation</title>
<p>Cell proliferation was evaluated as the rate of DNA synthesis by [<sup>3</sup>H]‐methylthymidine incorporation (Somasundaram and El‐Deiry, <xref ref-type="ref" rid="mol212363-bib-0031">1997</xref>). Cells were pooled in 24‐well plates until they reached 80% confluence, and then, the indicated chemicals were added and incubated for 24 h. At the end of the treatment, cells were incubated with serum‐free media containing <sup>3</sup>H‐methylthymidine (0.5 μCi per well) for 2 h and then washed twice with PBS. Cellular DNA was precipitated by 10% trichloroacetic acid and solubilized with 0.4 <sc>m</sc> NaOH (0.5 mL per well). Incorporation of <sup>3</sup>H‐methylthymidine into DNA was measured in a scintillation counter and was determined as counts per minute (CPM) (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0023">
<title>Colony formation in soft agar</title>
<p>This assay is a method for evaluating the ability of individual cell lines to grow in an anchorage‐independent manner. Cells were resuspended in DMEM containing 5% FBS with 0.3% agarose and layered on top of 0.5% agarose in DMEM on 60‐mm plates. A total of 1000 cells were seeded in 60‐mm soft agar dishes for 30 days, the dishes were examined twice per week, and colonies that grew beyond 50 mm in diameter were scored as positive. Each experiment was carried out in quadruplicate (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
<sec id="mol212363-sec-0024">
<title>Migration and invasion assays</title>
<p>Cell migration and invasion assays were performed in 24‐well chemotaxis plates with an 8‐μm polycarbonate filter membrane, uncoated for migration assays, or coated with 20 μg Matrigel for invasion assays. Invasion or migration was expressed as the number of migrated cells bound per microscopic field and averaged from at least four fields per assay in at least four experiments (Han <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0016">2008</xref>; Yu <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0038">2018</xref>).</p>
</sec>
</sec>
<sec id="mol212363-sec-0025">
<title>Animals</title>
<p>The BALB/c athymic nude male mice (6 weeks old) were obtained from the Disease Prevention Center of Guangdong Province. All procedures involving mice were conducted in accordance with NIH regulations concerning the use and care of experimental animals and were approved by the Institutional Animal Care and Use Committee (from Peking University Shenzhen Hospital). The 2x10<sup>6</sup> viable treated tumor cells were washed, harvested in PBS, and then injected into the lateral tail vein in a volume of 0.1 mL. Mice were monitored for changes in body weight and sacrificed when values fell below 20% of their initial weight. The lungs from sacrificed mice were isolated and fixed in 10% formalin. The number of surface metastases per lung was determined under a dissecting microscope. Formalin‐fixed, paraffin‐embedded tumor tissue from the lungs was sectioned to 4 mm thickness, and the histopathological analyses were performed with H&amp;E staining. Images were taken using a Carl Zeiss MIRAX MIDI slide scanner, and analyses were performed using a 3DHISTECH Pannoramic Viewer. The tumor tissues were isolated for <italic>in vivo</italic> monitoring of superoxide anion release, and the gene expression of PGC1β and LDHA from tumor tissues was measured by real‐time PCR for mRNA (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0026">
<title>
<italic>In vivo</italic> superoxide release</title>
<p>The superoxide anion (<mml:math id="nlm-math-1"><mml:msubsup><mml:mi mathvariant="normal">O</mml:mi><mml:mn>2</mml:mn><mml:mo>−</mml:mo></mml:msubsup></mml:math>) release from the tumor tissue was determined by a luminol/EDTA/Fe enhanced chemiluminescence (CL) system supplemented with DMSO/TBAC (dimethyl sulfoxide/tetrabutylammonium chloride) solution for extraction of released O<sub>2</sub>
<sup>.−</sup> from tissues as described previously (Yao <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0037">2005</xref>). The superoxide levels were calculated from the standard curve generated by the xanthine/xanthine oxidase reaction (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
<sec id="mol212363-sec-0027">
<title>Statistical analysis</title>
<p>The data are given as mean ± SEM; all of the experiments were performed at least in quadruplicate and three biological replicates were conducted for each experiment unless otherwise indicated. The one‐way ANOVA followed by the Bonferroni post hoc test was used to determine the statistical significance of different groups. The mouse survival curve was determined by Kaplan–Meier survival analysis using <sc>spss</sc> 22 software, and a <italic>P</italic> value &lt; 0.05 was considered significant (Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0040">2017</xref>).</p>
</sec>
</sec>
<sec id="mol212363-sec-0028">
<title>Results</title>
<sec id="mol212363-sec-0029">
<title>Increased LDHA expression in multiple myeloma cells is regulated by PGC1β</title>
<p>We first measured the gene expression of PGC1β and three isoforms of LDH in different multiple myeloma (MM) cell lines. As shown in Fig <xref ref-type="fig" rid="mol212363-fig-0001">1</xref>A, isolated primary normal B lymphocytes (NBL), several multiple myeloma cells lines, including U266B1, RPMI8226, and MM.1R, and CD138+ (isolated multiple myeloma cells from patients) were used for mRNA analysis. It showed that the mRNA expression for both PGC1β and LDHA was significantly increased in MM cells compared to NBL cells, while there was no difference for LDHB and LDHC. This suggests that MM cells have increased expression of PGC1β and LDHA. We then measured the protein levels in those cells (see Fig. <xref ref-type="fig" rid="mol212363-fig-0001">1</xref>B,C) and confirmed that the gene expression of PGC1β and LDHA was significantly increased in MM cell lines compared to NBL cells. We also measured the gene expression for another two isoforms of the PGC1 family, including PGC1α (Wu <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0036">1999</xref>) and PPRC1 (Gleyzer and Scarpulla, <xref ref-type="ref" rid="mol212363-bib-0013">2016</xref>), and no difference was observed for these genes (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S1</xref>A). We then evaluated the potential role of PGC1β on the contribution of LDHA expression. In Fig. <xref ref-type="fig" rid="mol212363-fig-0001">1</xref>D, the primary isolated NBL cells were infected by PGC1β lentivirus (↑PGC1β), and the primary CD138+ MM cells were knocked down by shPGC1β. The results showed that PGC1β infection (NBL/↑PGC1β) significantly increased mRNA expression of PGC1β and LDHA compared to the NBL control (NBL/CTL) group, while PGC1β lentivirus knockdown in CD138+ cells (CD138 + /shPGC1β) significantly decreased the expression of PGC1β and LDHA compared to the CD138+ control (CD138 + /CTL) group. On the other hand, there was no expression difference in LDHB and LDHC. We also measured the protein expression in those cells, and a pattern similar to that of mRNA expression was observed for the protein levels of PGC1β and LDHA (see Fig. <xref ref-type="fig" rid="mol212363-fig-0001">1</xref>E,F). Furthermore, we measured the gene expression of PGC1α and PPRC1, and no difference was found (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S1</xref>B). Our results indicate that LDHA may be regulated by PGC1β instead of PGC1α and PPRC1, while LDHB and LDHC are not regulated by PGC1β. Next, we investigated the effect of PGC1β on the expression of LDHA in other MM cell lines (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S2</xref>). The results showed that PGC1β overexpression (↑PGC1β) increased, while PGC1β knockdown (shPGC1β) decreased LDHA expression in U266B1 (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S2</xref>A), RPMI8226 (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S2</xref>B), and MM.1R cells (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S2</xref>C). Our results indicate that LDHA is regulated by PGC1β in all of the multiple myeloma cells.</p>
<fig fig-type="Figure" id="mol212363-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Increased <styled-content style="fixed-case">LDHA</styled-content> expression in multiple myeloma cells is regulated by <styled-content style="fixed-case">PGC</styled-content>1β. (A–C) Different cells, including isolated normal B lymphocytes (<styled-content style="fixed-case">NBL</styled-content>), <styled-content style="fixed-case">CD</styled-content>138‐positive multiple myeloma cells (<styled-content style="fixed-case">CD</styled-content>138+), and multiple myeloma cells lines U266B1, <styled-content style="fixed-case">RPMI</styled-content>8226, and <styled-content style="fixed-case">MM</styled-content>.1R, were used for gene analysis. (A) <styled-content style="fixed-case">mRNA</styled-content> level by <styled-content style="fixed-case">qPCR</styled-content>,<italic> n</italic> = 4. (B) Representative pictures for western blotting. (C) Quantitation of protein levels for (B), <italic>n</italic> = 5. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">NBL</styled-content> group. (D–F) The <styled-content style="fixed-case">NBL</styled-content> cells were infected by <styled-content style="fixed-case">PGC</styled-content>1β lentivirus (↑<styled-content style="fixed-case">PGC</styled-content>1β), the <styled-content style="fixed-case">CD</styled-content>138+ <styled-content style="fixed-case">MM</styled-content> cells were knocked down by <styled-content style="fixed-case">PGC</styled-content>1β (sh<styled-content style="fixed-case">PGC</styled-content>1β) lentivirus, and the cells were used for gene analysis. (D) <styled-content style="fixed-case">mRNA</styled-content> level by <styled-content style="fixed-case">qPCR</styled-content>,<italic> n</italic> = 4. (E) Representative pictures for western blotting. (F) Quantitation of protein levels for (E), <italic>n</italic> = 5. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">NBL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05 vs <styled-content style="fixed-case">CD</styled-content>138+/<styled-content style="fixed-case">CTL</styled-content> group. Data are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way ANOVA.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="MOL2-12-1579-g001"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0030">
<title>PGC1β regulates LDHA expression through PGC1β‐mediated increased RXRβ binding ability on the LDHA promoter</title>
<p>We investigated the molecular mechanism for PGC1β‐regulated LDHA expression in MM cells. A series of progressive 5′‐promoter deletion constructs for the LDHA promoter was generated, and those constructs were transfected into MM.1R cells for the reporter activity assay. We found that PGC1β‐induced reporter activities were not markedly changed among the −2000, −1500, −1000, −500, −400, −300, −200, and −100 deletion constructs (numbered according to Ensembl Transcript ID: ENST00000227157.8; transcription start site was marked as 0). However, activity was reduced by ~10‐fold in the pLDHA‐0 deletion reporter construct compared to the full‐length LDHA reporter (pLDHA‐2000), indicating that PGC1β‐responsive transcriptional element is located in the range of −100~0 on the LDHA promoter (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>A). The transcription factor database TESS revealed several potential binding motifs, including RXRβ sites located at −76 and −32, respectively, marked with red color (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>B). We then deleted those potential binding motifs, and the LDHA deletion reporter assay showed that deletion of RXRβ binding motif at either −76 (Δ‐76/RXRβ) or −32 (Δ‐32/RXRβ) significantly decreased PGC1β‐induced LDHA reporter activity compared to full‐length LDHA (pLDHA‐2000) reporter (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>C). We further deleted both RXRβ binding motifs at −73 and −32 (Δ‐76/‐32(RXRβ)) for the LDHA reporter activity assay (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>D). The results showed that RXRβ binding motif double‐deletion (Δ‐76/‐32(RXRβ)) reporter activity had a significant decrease compared to the single RXRβ binding motif reporter and had no significant difference compared to LDHA full‐length truncate reporter (pLDHA‐0), indicating that double RXRβ binding motifs at −73 and −32 [Δ‐76/‐32(RXRβ)] are required for PGC1β‐induced LDHA activation. We also measured the binding abilities of PGC1β, RXRα, and RXRβ on the LDHA promoter using the chromatin Immunoprecipitation (ChIP) technique in different MM cells (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>E). The results showed that the binding ability of PGC1β and RXRβ on the LDHA promoter was significantly increased in MM cells compared to the NBL control group, while the binding ability of RXRα on the LDHA promoter showed no difference, indicating that PGC1β and RXRβ may bind to the LDHA promoter and be responsible for LDHA activation, while RXRα has no effect. Finally, the siRNA technique was used to knock down those transcription factors to investigate their potential contribution on LDHA expression. We found that PGC1β knockdown (siPGC1β) not only largely reduced PGC1β basal expression by 77%, but also reduced LDHA expression by 64%; RXRα knockdown (siRXRα) only reduced RXRα expression by 66%, but had no effect on the expression of LDHA, PGC1β, or RXRβ; RXRβ knockdown (siRXRβ) reduced RXRβ basal expression by 71% and reduced LDHA expression by 68%, and had no effect on RXRα expression. Our results indicate that PGC1β and RXRβ contribute to LDHA expression, while RXRα has no effect (see Fig. <xref ref-type="fig" rid="mol212363-fig-0002">2</xref>F).</p>
<fig fig-type="Figure" id="mol212363-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>
<styled-content style="fixed-case">PGC</styled-content>1β regulates <styled-content style="fixed-case">LDHA</styled-content> expression through <styled-content style="fixed-case">PGC</styled-content>1β‐mediated increased <styled-content style="fixed-case">RXR</styled-content>β binding ability on the <styled-content style="fixed-case">LDHA</styled-content> promoter. (A) The <styled-content style="fixed-case">MM</styled-content>.1R cells were infected by either <styled-content style="fixed-case">PGC</styled-content>1β (↑<styled-content style="fixed-case">PGC</styled-content>1β) or empty control (<styled-content style="fixed-case">CTL</styled-content>) lentivirus for 2 days, and then, cells were transiently transfected by either <styled-content style="fixed-case">LDHA</styled-content> full‐length (<styled-content style="fixed-case">pLDHA</styled-content>‐2000) or deletion reporter plasmids. After 24 h, the <styled-content style="fixed-case">PGC</styled-content>1β‐induced <styled-content style="fixed-case">LDHA</styled-content> reporter activities from <styled-content style="fixed-case">PGC</styled-content>1β lentivirus‐infected cells (↑<styled-content style="fixed-case">PGC</styled-content>1β) were calculated as the relative percentage (% control) by comparing to lentivirus empty control (<styled-content style="fixed-case">CTL</styled-content>)‐infected cells. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">pLDHA</styled-content>‐2000 group, <italic>n</italic> = 4. (B) The schematic picture for the potential transcriptional binding motif in the range of −100~0 (from transcription start site) on the <styled-content style="fixed-case">LDHA</styled-content> promoter, and the two potential <styled-content style="fixed-case">RXR</styled-content>β binding sites are marked with red color. (C) The lentivirus‐infected <styled-content style="fixed-case">MM</styled-content>.1R cells were transiently transfected by either <styled-content style="fixed-case">LDHA</styled-content> full‐length (<styled-content style="fixed-case">pLDHA</styled-content>‐2000) or the specific transcriptional binding motif deletion reporter plasmids, and then, after 24 h, the reporter activities were measured. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">pLDHA</styled-content>‐2000 group, <italic>n</italic> = 4. (D) The lentivirus‐infected <styled-content style="fixed-case">MM</styled-content>.1R cells were transiently transfected by either <styled-content style="fixed-case">LDHA</styled-content> full‐length reporter (<styled-content style="fixed-case">pLDHA</styled-content>‐2000), <styled-content style="fixed-case">RXR</styled-content>β deletion plasmids of either Δ‐76, Δ‐32, or both Δ‐76/‐32, or full‐length truncate reporter (<styled-content style="fixed-case">pLDHA</styled-content>‐0) plasmids, and after 24 h, the reporter activities were measured. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">pLDHA</styled-content>‐2000 group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs Δ‐76(<styled-content style="fixed-case">RXR</styled-content>β) group, <italic>n</italic> = 4. (E) Different <styled-content style="fixed-case">MM</styled-content> cells were used for Ch<styled-content style="fixed-case">IP</styled-content> analysis by <styled-content style="fixed-case">PGC</styled-content>1β, <styled-content style="fixed-case">RXR</styled-content>α, or <styled-content style="fixed-case">RXR</styled-content>β antibody, respectively, and the <styled-content style="fixed-case">LDHA</styled-content> promoter in the range of −200~0 was amplified and measured by <styled-content style="fixed-case">qPCR</styled-content>,<italic> n</italic> = 5. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">NBL</styled-content> group. (F) The <styled-content style="fixed-case">MM</styled-content>.1R cells were transfected by si<styled-content style="fixed-case">RNA</styled-content> for either nonsense control (<styled-content style="fixed-case">CTL</styled-content>), <styled-content style="fixed-case">PGC</styled-content>1β, <styled-content style="fixed-case">RXR</styled-content>α, or <styled-content style="fixed-case">RXR</styled-content>β for 2 days, and then, the cells were harvested for <styled-content style="fixed-case">mRNA</styled-content> analysis. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group, <italic>n</italic> = 5. Results are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way ANOVA.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="MOL2-12-1579-g002"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0031">
<title>Overexpression of PGC1β or LDHA potentiates glycolytic metabolism, while knockdown of PGC1β or LDHA reverses this effect in MM.1R cells</title>
<p>We evaluated the potential contribution of PGC1β/LDHA expression on glycolysis metabolism in MM.1R cells. First, the PGC1β or LDHA was either overexpressed or knocked down by a lentivirus vector, and the related gene expression for PGC1β or LDHA was evaluated. In Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>A, overexpression of PGC1β (↑PGC1β) increased mRNA of PGC1β and LDHA by 289% and 195%, respectively; overexpression of LDHA (↑LDHA) increased LDHA mRNA by 269%, but had no effect on PGC1β level. On the other hand, PGC1β knockdown (shPGC1β) reduced mRNA of PGC1β and LDHA by 79% and 66% respectively; LDHA knockdown (shLDHA) reduced LDHA mRNA level by 77%, but had no effect on PGC1β. We then measured the protein levels of PGC1β and LDHA on the lentivirus‐manipulated cells (see Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>B,C), and it was observed that protein levels showed a pattern similar to that of the mRNA levels. Our results indicate that manipulation of PGC1β/LDHA expression by lentivirus vector was successful and efficient, and the expression of PGC1β modulates LDHA expression, while LDHA expression does not affect PGC1β expression. This further proves that LDHA is the downstream target gene of PGC1β. We then evaluated the basal glycolytic metabolism by ECAR (extracellular acidification rate) and OCR (oxygen consumption rate) using Seahorse‐XF96 Analyzer. We first measured the ECAR (see Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>D), and it showed that overexpression of PGC1β and LDHA increased ECAR by 168% and 154%, respectively, while knockdown of PGC1β and LDHA decreased ECAR by 57% and 42%, respectively. We then measured the OCR (see Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>E) and found that overexpression of PGC1β increased OCR by 156%, knockdown of PGC1β reduced OCR by 58%, and expression of LDHA showed no effect on OCR. Our results indicate that expression of PGC1β and LDHA modulates glycolytic metabolism as indicated by ECAR, and PGC1β expression modulates oxygen consumption, while LDHA expression shows no substantial effect on OCR. Finally, we measured the potential effect of PGC1β and LDHA on extracellular lactate production and intracellular LDH activity. In Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>F, overexpression of PGC1β and LDHA increased lactate production by 150% and 133%, respectively, while knockdown of PGC1β and LDHA reduced lactate production by 47% and 40%, respectively. Furthermore, overexpression of PGC1β and LDHA increased LDH activity by 203% and 274%, respectively, while knockdown of PGC1β and LDHA reduced LDH activity by 55% and 73%, respectively (see Fig. <xref ref-type="fig" rid="mol212363-fig-0003">3</xref>G). Our results further confirm that expression of PGC1β and LDHA potentiates glycolytic metabolism in MM cells.</p>
<fig fig-type="Figure" id="mol212363-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Expression of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> potentiates glycolysis metabolism, while knockdown of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> reverses the effect in <styled-content style="fixed-case">MM</styled-content>.1R cells. The <styled-content style="fixed-case">MM</styled-content>.1R cells were infected by either expression or knockdown lentivirus for either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content>, and the subsequent stable cell lines or related empty vector control (<styled-content style="fixed-case">CTL</styled-content>) was cultured in hypoxic conditions (94% N<sub>2</sub>, 5% <styled-content style="fixed-case">CO</styled-content>
<sub>2</sub>, and 1% O<sub>2</sub>) for 2 days. The cells were then harvested for further analysis. (A) <styled-content style="fixed-case">mRNA</styled-content> level by <styled-content style="fixed-case">qPCR</styled-content>,<italic> n</italic> = 4. (B) Quantitation of protein levels by western blotting, <italic>n</italic> = 5. (C) Representative pictures for (B). (D) <styled-content style="fixed-case">ECAR</styled-content> assay by Seahorse analysis, <italic>n</italic> = 4. (E) <styled-content style="fixed-case">OCR</styled-content> assay by Seahorse analysis, <italic>n</italic> = 4. (F) Lactate production in culture media, <italic>n</italic> = 5. (G) <styled-content style="fixed-case">LDH</styled-content> activity in treated cells, <italic>n</italic> = 5. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group. Results are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way ANOVA.</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="MOL2-12-1579-g003"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0032">
<title>Expression of PGC1β or LDHA modulates ROS generation, mitochondrial function, and apoptosis in MM.1R cells</title>
<p>We evaluated the potential effect of PGC1β/LDHA expression on cellular functions, including ROS formation, mitochondrial function, and apoptosis. We first measured ROS formation in treated MM.1R cells (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>A). It showed that overexpression of PGC1β and LDHA slightly increased ROS formation by 145% and 151%, respectively, and PGC1β knockdown (shPGC1β) largely increased ROS formation by 211%. Meanwhile, LDHA knockdown (shLDHA) had a smaller effect than shPGC1β group, increasing ROS formation by 159%. Our results indicate that PGC1β knockdown (shPGC1β) may result in significant cytotoxicity due to highest ROS formation. We then measured mitochondrial DNA copies (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>B). We found that LDHA expression showed no effect on mitochondrial DNA replication. On the other hand, PGC1β overexpression increased mitochondrial DNA copies by 245%, while PGC1β knockdown reduced mitochondrial DNA copies by 53%. This indicates that PGC1β regulates mitochondrial DNA replication, while LDHA does not. We also measured the intracellular ATP level (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>C). We found that overexpression of PGC1β and LDHA slightly increased ATP generation by 124% and 121%, respectively, and PGC1β knockdown (shPGC1β) reduced ATP generation by 47%, while LDHA knockdown (shLDHA) had a smaller effect than shPGC1β treatment, reducing ATP generation by 24% compared to the control (CTL) group. Finally, we measured apoptosis rate (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>D) and caspase‐3 activity (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>E). We found that overexpression of PGC1β and LDHA had no effect on apoptosis rate and caspase‐3 activity, and PGC1β knockdown (shPGC1β) increased apoptosis rate and caspase‐3 activity by 557% and 355%, respectively, while LDHA knockdown had a smaller effect than PGC1β knockdown, increasing apoptosis rate and caspase‐3 activity by 300% and 266%, respectively. Our results indicate that expression of PGC1β or LDHA modulates cellular function in MM.1R cells. In addition, our results showed a good correlation between ROS formation (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>A) and apoptosis rate (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>D) and caspase‐3 activity (see Fig. <xref ref-type="fig" rid="mol212363-fig-0004">4</xref>E). We then measured the effect of vitamin E derivative Trolox, and the results showed that antioxidant Trolox significantly decreased ROS formation in those cells (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S3</xref>A), while it did not change the effect on apoptosis rate (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S3</xref>B) and caspase‐3 activity (see Fig. <xref ref-type="supplementary-material" rid="mol212363-sup-0001">S3</xref>C), indicating that ROS formation is not the cause of cell apoptosis. Instead, both ROS formation and cell apoptosis may be the subsequent consequence of PGC1β/LDHA overexpression/knockdown.</p>
<fig fig-type="Figure" id="mol212363-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>Expression of either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> modulates <styled-content style="fixed-case">ROS</styled-content> generation, mitochondrial function, and apoptosis in <styled-content style="fixed-case">MM</styled-content>.1R cells. <styled-content style="fixed-case">MM</styled-content>.1R cells were infected by either expression or knockdown lentivirus for either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content>, and the subsequent stable cell lines or related empty vector control (<styled-content style="fixed-case">CTL</styled-content>) was cultured in hypoxic conditions (94% N<sub>2</sub>, 5% <styled-content style="fixed-case">CO</styled-content>
<sub>2</sub>, and 1% O<sub>2</sub>) for 2 days, and then, the cells were harvested for further analysis. (A) <styled-content style="fixed-case">ROS</styled-content> formation, <italic>n</italic> = 5. (B) Mitochondrial <styled-content style="fixed-case">DNA</styled-content> copies, <italic>n</italic> = 4. (C) Intracellular <styled-content style="fixed-case">ATP</styled-content> level, <italic>n</italic> = 5. (D) Apoptosis rate by <styled-content style="fixed-case">TUNEL</styled-content> assay, <italic>n</italic> = 5. (E) Caspase‐3 activity, <italic>n</italic> = 5. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs ↑<styled-content style="fixed-case">PGC</styled-content>1β group; <sup>#</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs sh<styled-content style="fixed-case">PGC</styled-content>1β group. Results are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way <styled-content style="fixed-case">ANOVA</styled-content>.</p>
</caption>
<graphic id="nlm-graphic-9" xlink:href="MOL2-12-1579-g004"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0033">
<title>Overexpression of PGC1β or LDHA potentiates cell proliferation, while knockdown of PGC1β or LDHA reverses the effect in MM.1R cells</title>
<p>We evaluated the potential effect of PGC1β/LDHA expression on <italic>in vitro</italic> cell proliferation in MM.1R cells. We first measured cell proliferation using thymidine incorporation (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>A) and metabolic activity using MTT assay (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>B). We found that PGC1β overexpression (↑PGC1β) increased thymidine incorporation and metabolic activity by 190% and 122%, respectively, while LDHA overexpression (↑LDHA treatment) had less of an effect than ↑PGC1β treatment, increasing thymidine incorporation and metabolic activity by 136% and 110%, respectively. Furthermore, PGC1β knockdown (shPGC1β) reduced thymidine incorporation and cell viability by 66% and 24%, respectively, while LDHA knockdown (shLDHA) reduced thymidine incorporation and cell viability by 29% and 12%, respectively, which showed less of an effect than shPGC1β treatment. We then measured the <italic>in vitro</italic> colony formation in soft agar (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>C). We found that overexpression of PGC1β (↑PGC1β) and LDHA (↑LDHA) increased colony formation by 158% and 136%, respectively, while knockdown of PGC1β (shPGC1β) and LDHA (shLDHA) reduced colony formation by 51% and 29%, respectively. We also measured the effect of PGC1β and LDHA on cell migration and invasion. The results showed that overexpression of PGC1β and LDHA increased cell migration by 251% and 178%, respectively, and knockdown of PGC1β and LDHA reduced cell migration by 68% and 55%, respectively (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>D). Furthermore, overexpression of PGC1β and LDHA increased cell invasion by 187% and 145%, respectively, and knockdown of PGC1β and LDHA reduced cell invasion by 61% and 44%, respectively (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>E). We finally measured the Ki‐67‐positive ratio using immunostaining (see Fig. <xref ref-type="fig" rid="mol212363-fig-0005">5</xref>F,G). Our results showed that overexpression of PGC1β (↑PGC1β) and LDHA (↑LDHA) increased Ki‐67‐positive ratio to 95% and 72%, respectively, from 54% basal ratio in the control (CTL) group, while knockdown of PGC1β (shPGC1β) and LDHA (shLDHA) decreased Ki‐67‐positive ratio to 18% and 36%, respectively, indicating that LDHA was significantly less effective than PGC1β. Our results show that expression of PGC1β or LDHA modulates <italic>in vitro</italic> cell proliferation, and PGC1β has a stronger effect than LDHA, indicating that PGC1β may contribute to tumor growth by some pathway other than regulation of LDHA expression.</p>
<fig fig-type="Figure" id="mol212363-fig-0005" orientation="portrait" position="float" xml:lang="en">
<label>Figure 5</label>
<caption>
<p>Expression of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> potentiates cell proliferation, while knockdown of <styled-content style="fixed-case">PGC</styled-content>1β and <styled-content style="fixed-case">LDHA</styled-content> reverses this effect in <styled-content style="fixed-case">MM</styled-content>.1R cells. The <styled-content style="fixed-case">MM</styled-content>.1R cells were infected by either expression or knockdown lentivirus for either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content>, the subsequent stable cell lines or related empty vector control (<styled-content style="fixed-case">CTL</styled-content>) were cultured in hypoxic conditions (94% N<sub>2</sub>, 5% <styled-content style="fixed-case">CO</styled-content>
<sub>2</sub>, and 1% O<sub>2</sub>) for 2 days, and then, the cells were harvested for further analysis. (A) Cell proliferation analysis by thymidine incorporation, <italic>n</italic> = 5. (B) Cell metabolic activity by <styled-content style="fixed-case">MTT</styled-content> assay, <italic>n</italic> = 5. (C) Colony formation assay in soft agar, <italic>n</italic> = 5. (D) Cell migration assay, <italic>n</italic> = 4. (E) Cell invasion assay, <italic>n</italic> = 4. (F) Quantitation of Ki‐67‐positive cells, <italic>n</italic> = 3. (G) Representative picture for (D). *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs ↑<styled-content style="fixed-case">PGC</styled-content>1β group; <sup>#</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs sh<styled-content style="fixed-case">PGC</styled-content>1β group. Results are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way <styled-content style="fixed-case">ANOVA</styled-content>.</p>
</caption>
<graphic id="nlm-graphic-11" xlink:href="MOL2-12-1579-g005"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0034">
<title>Overexpression of PGC1β or LDHA potentiates multiple myeloma tumor growth in <italic>in vivo</italic> xenograft tumor development, while knockdown of PGC1β or LDHA reverses the effect</title>
<p>We evaluated the effect of PGC1β/LDHA expression on the <italic>in vivo</italic> xenograft tumor development study using treated MM.1R cells. In Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>, the nude mice were injected through the tail vein with MM.1R cells, and the subsequent xenograft tumor tissues from the lungs were isolated and analyzed, and mouse survival was calculated. We first measured mRNA expression from tumor tissues for PGC1β and LDHA (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>A). The results showed that PGC1β overexpression (↑PGC1β) treatment increased PGC1β expression by 168%, and PGC1β knockdown (shPGC1β) treatment reduced PGC1β expression by 59%, while LDHA manipulation did not show any effect on PGC1β expression. On the other hand, LDHA expression was significantly increased by 145% or 164% respectively with the treatment of either PGC1β or LDHA overexpression, and LDHA expression was reduced to 45% or 36% respectively with the treatment of either PGC1β or LDHA knockdown. We also measured the protein expression in the cells, and a pattern similar to that of mRNA expression was observed for the protein levels of PGC1β and LDHA (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>B,C). Our results indicate that lentivirus‐carrying PGC1β/LDHA manipulation in MM.1R cells works efficiently and that LDHA is a potential downstream target gene of PGC1β. We then measured superoxide anion (<mml:math id="nlm-math-2"><mml:msubsup><mml:mi mathvariant="normal">O</mml:mi><mml:mn>2</mml:mn><mml:mo>−</mml:mo></mml:msubsup></mml:math>) release from the xenograft tumor tissues (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>D). We found that overexpression of either PGC1β or LDHA had no effect, while knockdown of either PGC1β or LDHA significantly increased superoxide anion release by 314% and 211%, respectively, and LDHA knockdown was significantly less effective than PGC1β knockdown. We then measured lung tumor nodule formation (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>E). We found that overexpression of PGC1β or LDHA increased tumor colony formation in the lung by 191% or 152%, respectively, while knockdown of PGC1β or LDHA reduced colony formation by 68% or 37%, respectively, and LDHA had significantly less of an effect than PGC1β in both overexpression and knockdown. We also evaluated the lung tumor spots by H&amp;E staining (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>F,G). We found that overexpression of PGC1β or LDHA increased lung tumor spots by 168% or 143%, respectively, and LDHA overexpression showed significantly less of an effect than PGC1β overexpression. On the other hand, knockdown of PGC1β or LDHA reduced lung tumor spots to 34% or 51%, respectively. We finally measured the mouse survival rate using Kaplan–Meier analysis (see Fig. <xref ref-type="fig" rid="mol212363-fig-0006">6</xref>H). The results showed that overexpression of PGC1β or LDHA significantly decreased mouse survival, while knockdown of PGC1β or LDHA largely increased mouse survival. Furthermore, PGC1β showed a significantly stronger effect than LDHA on the regulation of tumor growth. Our results indicate that PGC1β regulates tumor growth not only by LDHA‐mediated glycolytic metabolism, but also by some other potential pathways.</p>
<fig fig-type="Figure" id="mol212363-fig-0006" orientation="portrait" position="float" xml:lang="en">
<label>Figure 6</label>
<caption>
<p>Overexpression of either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> potentiates multiple myeloma tumor growth in <italic>in vivo</italic> xenograft tumor development, while knockdown of either <styled-content style="fixed-case">PGC</styled-content>1β or <styled-content style="fixed-case">LDHA</styled-content> reverses the effect. The nude mice were injected with treated <styled-content style="fixed-case">MM</styled-content>.1R cells through the tail vein for <italic>in vivo</italic> xenograft tumor development study, and the treated mice were sacrificed for further analysis. (A) <styled-content style="fixed-case">mRNA</styled-content> level by <styled-content style="fixed-case">qPCR</styled-content>. <italic>n</italic> = 4, *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group. (B) Quantitation of protein levels for western blotting. (C) Representative pictures for (B), <italic>n</italic> = 5. (D) Superoxide anion release from tumor tissues. <italic>n</italic> = 5, *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs sh<styled-content style="fixed-case">PGC</styled-content>1β group. (E–G) Mice were killed upon 20% weight loss, and the lungs were harvested for terminal analysis. The metastatic tumor nodules from the lungs were counted, and then, the formalin‐fixed, paraffin‐embedded tumor tissue from the lung was sectioned to 4 mm thickness, and the histopathological analyses were performed with H&amp;E staining. Images were taken using a Carl Zeiss <styled-content style="fixed-case">MIRAX MIDI</styled-content> slide scanner, and the lung tumor spots were analyzed using a 3<styled-content style="fixed-case">DHISTECH</styled-content> Pannoramic Viewer. (E) Tumor colony formation in lung, <italic>n</italic> = 9. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs ↑<styled-content style="fixed-case">PGC</styled-content>1β group; <sup>#</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs sh<styled-content style="fixed-case">PGC</styled-content>1β group. (F) Quantitated lung tumor spots, <italic>n</italic> = 6. *<italic>P </italic>&lt;<italic> </italic>0.05, vs <styled-content style="fixed-case">CTL</styled-content> group; <sup>¶</sup>
<italic>P </italic>&lt;<italic> </italic>0.05, vs ↑<styled-content style="fixed-case">PGC</styled-content>1β group. (G) Representative picture by H&amp;E staining. (H) Kaplan–Meier analysis comparing survival of mice between each treatment group; <italic>P</italic> value represents log‐rank Mantel–Cox test result, <italic>n</italic> = 9. Results are expressed as mean ± <styled-content style="fixed-case">SEM</styled-content>, and the group differences were statistically significant by one‐way ANOVA.</p>
</caption>
<graphic id="nlm-graphic-13" xlink:href="MOL2-12-1579-g006"></graphic>
</fig>
</sec>
</sec>
<sec id="mol212363-sec-0035">
<title>Discussion</title>
<p>In this study, we demonstrate that PGC1β and LDHA are highly expressed in MM cells, and LDHA is regulated by the PGC1β/RXRβ signaling pathway. Overexpression of PGC1β or LDHA significantly potentiates glycolysis metabolism, while knockdown of PGC1β or LDHA suppresses glycolysis metabolism with decreased cell proliferation and tumor growth.</p>
<sec id="mol212363-sec-0036">
<title>LDHA‐mediated glycolysis metabolism</title>
<p>The LDHA plays an important role in regulating glycolysis metabolism in MM cells. We show that LDHA expression under normoxic conditions potentiates extracellular acidification (ECAR) with increased lactate production and LDH enzyme activity, but oxygen consumption rate does not change, suggesting that LDHA promotes glycolysis in tumor cells even with an adequate oxygen supply (Bernacchioni <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0002">2017</xref>). This indicates that high rates of glycolysis in many tumors are required and necessary for tumor growth and are not just compensation for mitochondrial dysfunction (Bui and Thompson, <xref ref-type="ref" rid="mol212363-bib-0003">2006</xref>; Fantin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0011">2006</xref>). Furthermore, we show that LDHA knockdown decreases intracellular ATP generation and cell proliferation, together with increased ROS formation and apoptosis rate, as well as suppressed <italic>in vivo</italic> tumor growth with significantly improved survival. Our results suggest that disruption of LDHA in multiple myeloma is a promising approach for new targeted therapies (Maiso <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0027">2015</xref>; Ooi and Gomperts, <xref ref-type="ref" rid="mol212363-bib-0029">2015</xref>).</p>
</sec>
<sec id="mol212363-sec-0037">
<title>PGC1β‐mediated cellular function</title>
<p>The PGC1β is a master coactivator that regulates energy metabolism and many cellular functions, including mitochondrial biogenesis, thermogenesis, fatty acid β oxidation, and gluconeogenesis (Bellafante <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0001">2014</xref>; Lin <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0023">2005a</xref>,<xref ref-type="ref" rid="mol212363-bib-0025">b</xref>). In this study, we show that PGC1β expression potentiates glycolysis metabolism with increased ECAR levels, lactate production, and LDH activity, which shows functions similar to those of LDHA expression (Konda <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0019">2017</xref>). On the other hand, PGC1β expression also potentiates oxygen consumption with increased mitochondrial DNA copies and intracellular ATP levels. This can be explained because PGC1β is the coactivator of NRF1; it binds and activates mitochondrial transcription factor A (mtTFA) (Lelliott <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0021">2006</xref>; Vianna <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0035">2006</xref>), which directly regulates mitochondrial DNA replication (Wu <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0036">1999</xref>). In addition, we show that PGC1β expression slightly increases ROS formation in MM cells (Gomez de Cedron <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0014">2017</xref>). This can be partly explained because PGC1β increases mitochondrial fusion by coactivating ERRα (estrogen‐related receptor α) and Mfn2 (Liesa <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0022">2008</xref>).</p>
</sec>
<sec id="mol212363-sec-0038">
<title>Targeting PGC1β/LDHA as a new antitumor strategy</title>
<p>We show that many MM cells have highly expressed PGC1β, and PGC1β overexpression increases cell proliferation and tumor growth. This is consistent with recent findings that PGC1β promotes tumorigenesis in many tissues through the PGC1/ERR signaling axis (Deblois <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0007">2010</xref>, <xref ref-type="ref" rid="mol212363-bib-0008">2013</xref>; Eichner <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0010">2010</xref>). In this study, we show that LDHA is upregulated by the PGC1β/RXRβ signaling pathway and partly contributes to tumorigenesis. Furthermore, we show that PGC1β knockdown (shPGC1β) suppresses glycolysis metabolism with decreased ECAR, ATP generation, and lactate production. In addition, it achieves high levels of ROS formation with increased apoptosis rate and severely suppresses cell proliferation and tumor growth. Interestingly, it has been reported that PGC1β knockout mice are protected from carcinogenesis (Bellafante <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0001">2014</xref>) and PGC1β expression can be regulated by c‐Myc, a key regulator for cell growth and proliferation (Soucek and Evan, <xref ref-type="ref" rid="mol212363-bib-0032">2010</xref>; Zhang <italic>et al</italic>., <xref ref-type="ref" rid="mol212363-bib-0039">2007</xref>). This indicates that targeting PGC1β or PGC1β expression‐related pathways may be a new approach for antitumor drug development. A clear conclusion of this study is that <italic>in vitro</italic> cell proliferation and <italic>in vivo</italic> tumor growth induced by PGC1β overexpression cannot be simply accounted for by regulation of LDHA overexpression, but rather by other pathways. This finding might have an impact on the effectiveness of targeting the PGC1β/LDHA pathway.</p>
</sec>
</sec>
<sec id="mol212363-sec-0039">
<title>Conclusions</title>
<p>Taken together, the mechanism for PGC1β‐mediated LDHA expression and glycolysis metabolism in MM cells can be conceptualized in Fig. <xref ref-type="fig" rid="mol212363-fig-0007">7</xref>. In Fig. <xref ref-type="fig" rid="mol212363-fig-0007">7</xref>A, the normal cells have PGC1β coactivation of RXRβ on the LDHA promoter with normal LDHA expression and OXPHOS (oxidative phosphorylation)‐dominated metabolism. In Fig. <xref ref-type="fig" rid="mol212363-fig-0007">7</xref>B, the cancer cells have PGC1β overexpression, causing the PGC1β to coactivate RXRβ, which in turn causes cells to have LDHA overexpression with glycolysis‐dominated metabolism, favoring cell proliferation. This is the first time the mechanism for PGC1β‐mediated LDHA expression in multiple myeloma has been identified, and this provides us with a novel antitumor strategy through targeting of the PGC1β/LDHA axis.</p>
<fig fig-type="Figure" id="mol212363-fig-0007" orientation="portrait" position="float" xml:lang="en">
<label>Figure 7</label>
<caption>
<p>Proposed mechanisms for <styled-content style="fixed-case">PGC</styled-content>1β‐mediated <styled-content style="fixed-case">LDHA</styled-content> expression and glycolysis metabolism in multiple myeloma cells. (A) <styled-content style="fixed-case">PGC</styled-content>1β‐mediated <styled-content style="fixed-case">OXPHOS</styled-content> metabolism in normal cells. (B) <styled-content style="fixed-case">PGC</styled-content>1β‐mediated glycolysis metabolism in cancer cells. <styled-content style="fixed-case">LDHA</styled-content>, lactate dehydrogenase A; <styled-content style="fixed-case">OXPHOS</styled-content>, oxidative phosphorylation; <styled-content style="fixed-case">PGC</styled-content>1β, peroxisome proliferator‐activated receptor‐γ (<styled-content style="fixed-case">PPAR</styled-content>γ) coactivator‐1β; <styled-content style="fixed-case">RXR</styled-content>β, retinoic X receptor β.</p>
</caption>
<graphic id="nlm-graphic-15" xlink:href="MOL2-12-1579-g007"></graphic>
</fig>
</sec>
<sec id="mol212363-sec-0041">
<title>Author contributions</title>
<p>PY wrote the manuscript. PY, WX, and WGX designed the study, analyzed the data, and interpreted the experiments. JF and QC prepared the CD138+ cells. ML, RZ, and XH performed statistical analysis and part of mouse experiments. YS and YL performed gene analysis. YZ and ZZ performed part of the mapping analysis. HZ and LL performed the remaining experiments. All authors read and approved the final manuscript.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="mol212363-sup-0001">
<caption>
<p>
<bold>Table S1.</bold> Sequences of primers for the real‐time quantitative PCR (qPCR).</p>
<p>
<bold>Fig. S1.</bold> Gene expression of PGC1α and PPRC1 shows no difference in multiple myeloma cells and is not regulated by PGC1β.</p>
<p>
<bold>Fig. S2.</bold> Gene expression of LDHA is regulated by PGC1β in different multiple myeloma cell lines.</p>
<p>
<bold>Fig. S3.</bold> The vitamin E derivative Trolox minimizes ROS formation, while it does not decrease apoptosis or caspase‐3 activity in PGC1β/LDHA overexpression/knockdown cells.</p>
</caption>
<media xlink:href="MOL2-12-1579-s001.doc">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="mol212363-sec-0040">
<title>Acknowledgements</title>
<p>This study was financially supported by The National Natural Science Foundation of China, Project #: 81772097; Natural Science Foundation of Hubei Province of China, Project #: 2016CFB473; Bureau of Public Health of Hainan Province, Key Project # 14A110065; Shenzhen Scientific and Technical Innovation Committee, Project #: JCYJ20150403091443305; and Shenzhen SanMing Project: SZSM201612004.</p>
</ack>
<ref-list content-type="cited-references" id="mol212363-bibl-0001">
<title>References</title>
<ref id="mol212363-bib-0001">
<mixed-citation id="mol212363-cit-0001" publication-type="journal">
<string-name>
<surname>Bellafante</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Morgano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Salvatore</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Murzilli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Di Tullio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>D'Orazio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Latorre</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Villani</surname>
<given-names>G</given-names>
</string-name> and <string-name>
<surname>Moschetta</surname>
<given-names>A</given-names>
</string-name> (<year>2014</year>) <article-title>PGC‐1beta promotes enterocyte lifespan and tumorigenesis in the intestine</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci USA
<volume>111</volume>, <fpage>E4523</fpage>–<lpage>E4531</lpage>.<pub-id pub-id-type="pmid">25288742</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0002">
<mixed-citation id="mol212363-cit-0002" publication-type="journal">
<string-name>
<surname>Bernacchioni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Ghini</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Cencetti</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Japtok</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Donati</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bruni</surname>
<given-names>P</given-names>
</string-name> and <string-name>
<surname>Turano</surname>
<given-names>P</given-names>
</string-name> (<year>2017</year>) <article-title>NMR metabolomics highlights sphingosine kinase‐1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells</article-title>. <source xml:lang="en"/>Mol Oncol
<volume>11</volume>, <fpage>517</fpage>–<lpage>533</lpage>.<pub-id pub-id-type="pmid">28258651</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0003">
<mixed-citation id="mol212363-cit-0003" publication-type="journal">
<string-name>
<surname>Bui</surname>
<given-names>T</given-names>
</string-name> and <string-name>
<surname>Thompson</surname>
<given-names>CB</given-names>
</string-name> (<year>2006</year>) <article-title>Cancer's sweet tooth</article-title>. <source xml:lang="en"/>Cancer Cell
<volume>9</volume>, <fpage>419</fpage>–<lpage>420</lpage>.<pub-id pub-id-type="pmid">16766260</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0004">
<mixed-citation id="mol212363-cit-0004" publication-type="journal">
<string-name>
<surname>Chang</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Kazmin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jasper</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kunder</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zuercher</surname>
<given-names>WJ</given-names>
</string-name> and <string-name>
<surname>McDonnell</surname>
<given-names>DP</given-names>
</string-name> (<year>2011</year>) <article-title>The metabolic regulator ERRalpha, a downstream target of HER2/IGF‐1R, as a therapeutic target in breast cancer</article-title>. <source xml:lang="en"/>Cancer Cell
<volume>20</volume>, <fpage>500</fpage>–<lpage>510</lpage>.<pub-id pub-id-type="pmid">22014575</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0005">
<mixed-citation id="mol212363-cit-0005" publication-type="journal">
<string-name>
<surname>Christofk</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Vander Heiden</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Harris</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Ramanathan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gerszten</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fleming</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Schreiber</surname>
<given-names>SL</given-names>
</string-name> and <string-name>
<surname>Cantley</surname>
<given-names>LC</given-names>
</string-name> (<year>2008</year>) <article-title>The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth</article-title>. <source xml:lang="en"/>Nature
<volume>452</volume>, <fpage>230</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">18337823</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0006">
<mixed-citation id="mol212363-cit-0006" publication-type="journal">
<string-name>
<surname>Dalva‐Aydemir</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bajpai</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Martinez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Adekola</surname>
<given-names>KU</given-names>
</string-name>, <string-name>
<surname>Kandela</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Singhal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Koblinski</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Raje</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Rosen</surname>
<given-names>ST</given-names>
</string-name>
<italic>et al</italic> (<year>2015</year>) <article-title>Targeting the metabolic plasticity of multiple myeloma with FDA‐approved ritonavir and metformin</article-title>. <source xml:lang="en"/>Clin Cancer Res
<volume>21</volume>, <fpage>1161</fpage>–<lpage>1171</lpage>.<pub-id pub-id-type="pmid">25542900</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0007">
<mixed-citation id="mol212363-cit-0007" publication-type="journal">
<string-name>
<surname>Deblois</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chahrour</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Perry</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Sylvain‐Drolet</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>WJ</given-names>
</string-name> and <string-name>
<surname>Giguere</surname>
<given-names>V</given-names>
</string-name> (<year>2010</year>) <article-title>Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC‐1beta promotes mammary gland tumorigenesis</article-title>. <source xml:lang="en"/>Cancer Res
<volume>70</volume>, <fpage>10277</fpage>–<lpage>10287</lpage>.<pub-id pub-id-type="pmid">20961995</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0008">
<mixed-citation id="mol212363-cit-0008" publication-type="journal">
<string-name>
<surname>Deblois</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>St‐Pierre</surname>
<given-names>J</given-names>
</string-name> and <string-name>
<surname>Giguere</surname>
<given-names>V</given-names>
</string-name> (<year>2013</year>) <article-title>The PGC‐1/ERR signaling axis in cancer</article-title>. <source xml:lang="en"/>Oncogene
<volume>32</volume>, <fpage>3483</fpage>–<lpage>3490</lpage>.<pub-id pub-id-type="pmid">23208510</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0009">
<mixed-citation id="mol212363-cit-0009" publication-type="journal">
<string-name>
<surname>Dimopoulos</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sogaard Helbo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fibiger Munch‐Petersen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sjo</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sommer Kristensen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Asmar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hermansen</surname>
<given-names>NEU</given-names>
</string-name>, <string-name>
<surname>O'Connel</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gimsing</surname>
<given-names>P</given-names>
</string-name>
<italic>et al</italic> (<year>2018</year>) <article-title>Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner</article-title>. <source xml:lang="en"/>Mol Oncol
<volume>12</volume>, <fpage>180</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">29130642</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0010">
<mixed-citation id="mol212363-cit-0010" publication-type="journal">
<string-name>
<surname>Eichner</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Perry</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Dufour</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Bertos</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>St‐Pierre</surname>
<given-names>J</given-names>
</string-name> and <string-name>
<surname>Giguere</surname>
<given-names>V</given-names>
</string-name> (<year>2010</year>) <article-title>miR‐378(*) mediates metabolic shift in breast cancer cells via the PGC‐1beta/ERRgamma transcriptional pathway</article-title>. <source xml:lang="en"/>Cell Metab
<volume>12</volume>, <fpage>352</fpage>–<lpage>361</lpage>.<pub-id pub-id-type="pmid">20889127</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0011">
<mixed-citation id="mol212363-cit-0011" publication-type="journal">
<string-name>
<surname>Fantin</surname>
<given-names>VR</given-names>
</string-name>, <string-name>
<surname>St‐Pierre</surname>
<given-names>J</given-names>
</string-name> and <string-name>
<surname>Leder</surname>
<given-names>P</given-names>
</string-name> (<year>2006</year>) <article-title>Attenuation of LDH‐A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance</article-title>. <source xml:lang="en"/>Cancer Cell
<volume>9</volume>, <fpage>425</fpage>–<lpage>434</lpage>.<pub-id pub-id-type="pmid">16766262</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0012">
<mixed-citation id="mol212363-cit-0012" publication-type="journal">
<string-name>
<surname>Fujiwara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kawano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yuki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Okuno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nosaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mitsuya</surname>
<given-names>H</given-names>
</string-name> and <string-name>
<surname>Hata</surname>
<given-names>H</given-names>
</string-name> (<year>2013</year>) <article-title>PDK1 inhibition is a novel therapeutic target in multiple myeloma</article-title>. <source xml:lang="en"/>Br J Cancer
<volume>108</volume>, <fpage>170</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">23321518</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0013">
<mixed-citation id="mol212363-cit-0013" publication-type="journal">
<string-name>
<surname>Gleyzer</surname>
<given-names>N</given-names>
</string-name> and <string-name>
<surname>Scarpulla</surname>
<given-names>RC</given-names>
</string-name> (<year>2016</year>) <article-title>Concerted action of PGC‐1‐related coactivator (PRC) and c‐MYC in the stress response to mitochondrial dysfunction</article-title>. <source xml:lang="en"/>J Biol Chem
<volume>291</volume>, <fpage>25529</fpage>–<lpage>25541</lpage>.<pub-id pub-id-type="pmid">27789709</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0014">
<mixed-citation id="mol212363-cit-0014" publication-type="journal">
<string-name>
<surname>Gomez de Cedron</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Acin Perez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Martinez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Molina</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Herranz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Feliu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reglero</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Enriquez</surname>
<given-names>JA</given-names>
</string-name> and <string-name>
<surname>Ramirez de Molina</surname>
<given-names>A</given-names>
</string-name> (<year>2017</year>) <article-title>MicroRNA‐661 modulates redox and metabolic homeostasis in colon cancer</article-title>. <source xml:lang="en"/>Mol Oncol
<volume>11</volume>, <fpage>1768</fpage>–<lpage>1787</lpage>.<pub-id pub-id-type="pmid">28981199</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0015">
<mixed-citation id="mol212363-cit-0015" publication-type="journal">
<string-name>
<surname>Gong</surname>
<given-names>JN</given-names>
</string-name>, <string-name>
<surname>Khong</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Riffkin</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Garnier</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Khaw</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Lessene</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Herold</surname>
<given-names>MJ</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1</article-title>. <source xml:lang="en"/>Blood
<volume>128</volume>, <fpage>1834</fpage>–<lpage>1844</lpage>.<pub-id pub-id-type="pmid">27465916</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0016">
<mixed-citation id="mol212363-cit-0016" publication-type="journal">
<string-name>
<surname>Han</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kohwi</surname>
<given-names>Y</given-names>
</string-name> and <string-name>
<surname>Kohwi‐Shigematsu</surname>
<given-names>T</given-names>
</string-name> (<year>2008</year>) <article-title>SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis</article-title>. <source xml:lang="en"/>Nature
<volume>452</volume>, <fpage>187</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">18337816</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0017">
<mixed-citation id="mol212363-cit-0017" publication-type="journal">
<string-name>
<surname>Jin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chun</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Alesi</surname>
<given-names>GN</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Magliocca</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>ZG</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Khuri</surname>
<given-names>FR</given-names>
</string-name>
<italic>et al</italic> (<year>2017</year>) <article-title>Phosphorylation‐mediated activation of LDHA promotes cancer cell invasion and tumour metastasis</article-title>. <source xml:lang="en"/>Oncogene
<volume>36</volume>, <fpage>3797</fpage>–<lpage>3806</lpage>.<pub-id pub-id-type="pmid">28218905</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0018">
<mixed-citation id="mol212363-cit-0018" publication-type="journal">
<string-name>
<surname>Joseph</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lefebvre</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Mereau‐Richard</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Danze</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Belin‐Plancot</surname>
<given-names>MT</given-names>
</string-name> and <string-name>
<surname>Formstecher</surname>
<given-names>P</given-names>
</string-name> (<year>1998</year>) <article-title>Evidence for the involvement of both retinoic acid receptor‐ and retinoic X receptor‐dependent signaling pathways in the induction of tissue transglutaminase and apoptosis in the human myeloma cell line RPMI 8226</article-title>. <source xml:lang="en"/>Blood
<volume>91</volume>, <fpage>2423</fpage>–<lpage>2432</lpage>.<pub-id pub-id-type="pmid">9516142</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0019">
<mixed-citation id="mol212363-cit-0019" publication-type="journal">
<string-name>
<surname>Konda</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Olivero</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Musiani</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lamba</surname>
<given-names>S</given-names>
</string-name> and <string-name>
<surname>Di Renzo</surname>
<given-names>MF</given-names>
</string-name> (<year>2017</year>) <article-title>Heat‐shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF</article-title>. <source xml:lang="en"/>Mol Oncol
<volume>11</volume>, <fpage>599</fpage>–<lpage>611</lpage>.<pub-id pub-id-type="pmid">28182330</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0020">
<mixed-citation id="mol212363-cit-0020" publication-type="journal">
<string-name>
<surname>Landgren</surname>
<given-names>O</given-names>
</string-name> and <string-name>
<surname>Morgan</surname>
<given-names>GJ</given-names>
</string-name> (<year>2014</year>) <article-title>Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice</article-title>. <source xml:lang="en"/>Clin Cancer Res
<volume>20</volume>, <fpage>804</fpage>–<lpage>813</lpage>.<pub-id pub-id-type="pmid">24270684</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0021">
<mixed-citation id="mol212363-cit-0021" publication-type="journal">
<string-name>
<surname>Lelliott</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Medina‐Gomez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Petrovic</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feldmann</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Bjursell</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>P</given-names>
</string-name>
<italic>et al</italic> (<year>2006</year>) <article-title>Ablation of PGC‐1beta results in defective mitochondrial activity, thermogenesis, hepatic function, and cardiac performance</article-title>. <source xml:lang="en"/>PLoS Biol
<volume>4</volume>, <fpage>e369</fpage>.<pub-id pub-id-type="pmid">17090215</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0022">
<mixed-citation id="mol212363-cit-0022" publication-type="journal">
<string-name>
<surname>Liesa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Borda‐d'Agua</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Medina‐Gomez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lelliott</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Paz</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Rojo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Palacin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vidal‐Puig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zorzano</surname>
<given-names>A</given-names>
</string-name> (<year>2008</year>) <article-title>Mitochondrial fusion is increased by the nuclear coactivator PGC‐1beta</article-title>. <source xml:lang="en"/>PLoS ONE
<volume>3</volume>, <fpage>e3613</fpage>.<pub-id pub-id-type="pmid">18974884</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0023">
<mixed-citation id="mol212363-cit-0023" publication-type="journal">
<string-name>
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Handschin</surname>
<given-names>C</given-names>
</string-name> and <string-name>
<surname>Spiegelman</surname>
<given-names>BM</given-names>
</string-name> (<year>2005a</year>) <article-title>Metabolic control through the PGC‐1 family of transcription coactivators</article-title>. <source xml:lang="en"/>Cell Metab
<volume>1</volume>, <fpage>361</fpage>–<lpage>370</lpage>.<pub-id pub-id-type="pmid">16054085</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0024">
<mixed-citation id="mol212363-cit-0024" publication-type="journal">
<string-name>
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Puigserver</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Donovan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tarr</surname>
<given-names>P</given-names>
</string-name> and <string-name>
<surname>Spiegelman</surname>
<given-names>BM</given-names>
</string-name> (<year>2002</year>) <article-title>Peroxisome proliferator‐activated receptor gamma coactivator 1beta (PGC‐1beta), a novel PGC‐1‐related transcription coactivator associated with host cell factor</article-title>. <source xml:lang="en"/>J Biol Chem
<volume>277</volume>, <fpage>1645</fpage>–<lpage>1648</lpage>.<pub-id pub-id-type="pmid">11733490</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0025">
<mixed-citation id="mol212363-cit-0025" publication-type="journal">
<string-name>
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tarr</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Handschin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Pei</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Uldry</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tontonoz</surname>
<given-names>P</given-names>
</string-name>
<italic>et al</italic> (<year>2005b</year>) <article-title>Hyperlipidemic effects of dietary saturated fats mediated through PGC‐1beta coactivation of SREBP</article-title>. <source xml:lang="en"/>Cell
<volume>120</volume>, <fpage>261</fpage>–<lpage>273</lpage>.<pub-id pub-id-type="pmid">15680331</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0026">
<mixed-citation id="mol212363-cit-0026" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>H</given-names>
</string-name> and <string-name>
<surname>Schubert</surname>
<given-names>D</given-names>
</string-name> (<year>1997</year>) <article-title>Mechanism of cellular 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) reduction</article-title>. <source xml:lang="en"/>J Neurochem
<volume>69</volume>, <fpage>581</fpage>–<lpage>593</lpage>.<pub-id pub-id-type="pmid">9231715</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0027">
<mixed-citation id="mol212363-cit-0027" publication-type="journal">
<string-name>
<surname>Maiso</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Huynh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moschetta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sacco</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Aljawai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mishima</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Asara</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Roccaro</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Kimmelman</surname>
<given-names>AC</given-names>
</string-name> and <string-name>
<surname>Ghobrial</surname>
<given-names>IM</given-names>
</string-name> (<year>2015</year>) <article-title>Metabolic signature identifies novel targets for drug resistance in multiple myeloma</article-title>. <source xml:lang="en"/>Cancer Res
<volume>75</volume>, <fpage>2071</fpage>–<lpage>2082</lpage>.<pub-id pub-id-type="pmid">25769724</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0028">
<mixed-citation id="mol212363-cit-0028" publication-type="journal">
<string-name>
<surname>Naymagon</surname>
<given-names>L</given-names>
</string-name> and <string-name>
<surname>Abdul‐Hay</surname>
<given-names>M</given-names>
</string-name> (<year>2016</year>) <article-title>Novel agents in the treatment of multiple myeloma: a review about the future</article-title>. <source xml:lang="en"/>J Hematol Oncol
<volume>9</volume>, <fpage>52</fpage>.<pub-id pub-id-type="pmid">27363832</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0029">
<mixed-citation id="mol212363-cit-0029" publication-type="journal">
<string-name>
<surname>Ooi</surname>
<given-names>AT</given-names>
</string-name> and <string-name>
<surname>Gomperts</surname>
<given-names>BN</given-names>
</string-name> (<year>2015</year>) <article-title>Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA</article-title>. <source xml:lang="en"/>Clin Cancer Res
<volume>21</volume>, <fpage>2440</fpage>–<lpage>2444</lpage>.<pub-id pub-id-type="pmid">25838393</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0030">
<mixed-citation id="mol212363-cit-0030" publication-type="journal">
<string-name>
<surname>Sherbenou</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Aftab</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Behrens</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Wiita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Logan</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Acosta‐Alvear</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hann</surname>
<given-names>BC</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Shuman</surname>
<given-names>MA</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>Antibody‐drug conjugate targeting CD46 eliminates multiple myeloma cells</article-title>. <source xml:lang="en"/>J Clin Invest
<volume>126</volume>, <fpage>4640</fpage>–<lpage>4653</lpage>.<pub-id pub-id-type="pmid">27841764</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0031">
<mixed-citation id="mol212363-cit-0031" publication-type="journal">
<string-name>
<surname>Somasundaram</surname>
<given-names>K</given-names>
</string-name> and <string-name>
<surname>El‐Deiry</surname>
<given-names>WS</given-names>
</string-name> (<year>1997</year>) <article-title>Inhibition of p53‐mediated transactivation and cell cycle arrest by E1A through its p300/CBP‐interacting region</article-title>. <source xml:lang="en"/>Oncogene
<volume>14</volume>, <fpage>1047</fpage>–<lpage>1057</lpage>.<pub-id pub-id-type="pmid">9070653</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0032">
<mixed-citation id="mol212363-cit-0032" publication-type="journal">
<string-name>
<surname>Soucek</surname>
<given-names>L</given-names>
</string-name> and <string-name>
<surname>Evan</surname>
<given-names>GI</given-names>
</string-name> (<year>2010</year>) <article-title>The ups and downs of Myc biology</article-title>. <source xml:lang="en"/>Curr Opin Genet Dev
<volume>20</volume>, <fpage>91</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="pmid">19962879</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0033">
<mixed-citation id="mol212363-cit-0033" publication-type="journal">
<string-name>
<surname>Teoh</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Sebastian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Choo</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Fonseca</surname>
<given-names>R</given-names>
</string-name> and <string-name>
<surname>Chng</surname>
<given-names>WJ</given-names>
</string-name> (<year>2014</year>) <article-title>p53 haploinsufficiency and functional abnormalities in multiple myeloma</article-title>. <source xml:lang="en"/>Leukemia
<volume>28</volume>, <fpage>2066</fpage>–<lpage>2074</lpage>.<pub-id pub-id-type="pmid">24625551</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0034">
<mixed-citation id="mol212363-cit-0034" publication-type="journal">
<string-name>
<surname>Usmani</surname>
<given-names>SZ</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Qu</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Petty</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Waheed</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shaughnessy</surname>
<given-names>JD</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Alsayed</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Heuck</surname>
<given-names>CJ</given-names>
</string-name>
<italic>et al</italic> (<year>2012</year>) <article-title>Primary plasma cell leukemia: clinical and laboratory presentation, gene‐expression profiling and clinical outcome with Total Therapy protocols</article-title>. <source xml:lang="en"/>Leukemia
<volume>26</volume>, <fpage>2398</fpage>–<lpage>2405</lpage>.<pub-id pub-id-type="pmid">22508408</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0035">
<mixed-citation id="mol212363-cit-0035" publication-type="journal">
<string-name>
<surname>Vianna</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Huntgeburth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Coppari</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Barbatelli</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tzameli</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>YB</given-names>
</string-name>, <string-name>
<surname>Cinti</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic> (<year>2006</year>) <article-title>Hypomorphic mutation of PGC‐1beta causes mitochondrial dysfunction and liver insulin resistance</article-title>. <source xml:lang="en"/>Cell Metab
<volume>4</volume>, <fpage>453</fpage>–<lpage>464</lpage>.<pub-id pub-id-type="pmid">17141629</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0036">
<mixed-citation id="mol212363-cit-0036" publication-type="journal">
<string-name>
<surname>Wu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Puigserver</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Andersson</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Adelmant</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mootha</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Troy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cinti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lowell</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Scarpulla</surname>
<given-names>RC</given-names>
</string-name>
<italic>et al</italic> (<year>1999</year>) <article-title>Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC‐1</article-title>. <source xml:lang="en"/>Cell
<volume>98</volume>, <fpage>115</fpage>–<lpage>124</lpage>.<pub-id pub-id-type="pmid">10412986</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0037">
<mixed-citation id="mol212363-cit-0037" publication-type="journal">
<string-name>
<surname>Yao</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Gou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yee Aw</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name> and <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name> (<year>2005</year>) <article-title>Fatty acid‐mediated intracellular iron translocation: a synergistic mechanism of oxidative injury</article-title>. <source xml:lang="en"/>Free Radic Biol Med
<volume>39</volume>, <fpage>1385</fpage>–<lpage>1398</lpage>.<pub-id pub-id-type="pmid">16257648</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0038">
<mixed-citation id="mol212363-cit-0038" publication-type="journal">
<string-name>
<surname>Yu</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>Benitez</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Plouffe</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Ryback</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Greenbaum</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Delatte</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Guan</surname>
<given-names>KL</given-names>
</string-name>
<italic>et al</italic> (<year>2018</year>) <article-title>YAP and MRTF‐A, transcriptional co‐activators of RhoA‐mediated gene expression, are critical for glioblastoma tumorigenicity</article-title>. <source xml:lang="en"/>Oncogene Epub ahead of print.</mixed-citation>
</ref>
<ref id="mol212363-bib-0039">
<mixed-citation id="mol212363-cit-0039" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Fukuda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Krishnamachary</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Zeller</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Dang</surname>
<given-names>CV</given-names>
</string-name> and <string-name>
<surname>Semenza</surname>
<given-names>GL</given-names>
</string-name> (<year>2007</year>) <article-title>HIF‐1 inhibits mitochondrial biogenesis and cellular respiration in VHL‐deficient renal cell carcinoma by repression of C‐MYC activity</article-title>. <source xml:lang="en"/>Cancer Cell
<volume>11</volume>, <fpage>407</fpage>–<lpage>420</lpage>.<pub-id pub-id-type="pmid">17482131</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0040">
<mixed-citation id="mol212363-cit-0040" publication-type="journal">
<string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>
<given-names>W</given-names>
</string-name> and <string-name>
<surname>Yao</surname>
<given-names>P</given-names>
</string-name> (<year>2017</year>) <article-title>Combination of betulinic acid and chidamide inhibits acute myeloid leukemia by suppression of the HIF1alpha pathway and generation of reactive oxygen species</article-title>. <source xml:lang="en"/>Oncotarget
<volume>8</volume>, <fpage>94743</fpage>–<lpage>94758</lpage>.<pub-id pub-id-type="pmid">29212263</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0041">
<mixed-citation id="mol212363-cit-0041" publication-type="journal">
<string-name>
<surname>Zou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ruan</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>
<italic>et al</italic> (<year>2017</year>) <article-title>Prenatal levonorgestrel exposure induces autism‐like behavior in offspring through ERbeta suppression in the amygdala</article-title>. <source xml:lang="en"/>Mol Autism
<volume>8</volume>, <fpage>46</fpage>.<pub-id pub-id-type="pmid">28824796</pub-id></mixed-citation>
</ref>
<ref id="mol212363-bib-0042">
<mixed-citation id="mol212363-cit-0042" publication-type="journal">
<string-name>
<surname>Zubair</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Azim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Srivastava</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Ahmad</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bhardwaj</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>
<italic>et al</italic> (<year>2016</year>) <article-title>Glucose metabolism reprogrammed by overexpression of IKKepsilon promotes pancreatic tumor growth</article-title>. <source xml:lang="en"/>Cancer Res
<volume>76</volume>, <fpage>7254</fpage>–<lpage>7264</lpage>.<pub-id pub-id-type="pmid">27923829</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>